Bibliographic Details
Title: |
Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. |
Authors: |
Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki |
Source: |
Cell Transplantation; Jan-Dec2023, Vol. 32, p1-14, 14p |
Subject Terms: |
CORD blood transplantation, GRAFT versus host disease, STEM cell transplantation, TREATMENT effectiveness, CYCLOPHOSPHAMIDE, ACUTE diseases |
Abstract: |
Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I-II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39, P = 0.018] and CBT (HR = 0.48, P < 0.001), but not after MDT (HR = 0.80, P = 0.267) compared with patients without acute GVHD. Grade I-II acute GVHD had a trend toward reducing the risk of nonrelapse mortality (NRM) after PTCy-haplo (HR = 0.13, P = 0.060) and this positive effect was significant after CBT (HR = 0.39, P = 0.003). A negative impact of grade III-IV acute GVHD on NRM was observed after CBT and MDT, but not after PTCy-haplo. Limited chronic GVHD had a positive impact on OS after CBT and MDT, but not after PTCy-haplo. In conclusion, mild acute GVHD improved outcomes after PTCy-haplo and CBT, and limited chronic GVHD improved outcomes after CBT and MDT. These data indicated that the effects of GVHD on transplant outcomes depended on transplant platforms. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cell Transplantation is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
Database: |
Complementary Index |